Welcome to our dedicated page for Healthlynked SEC filings (Ticker: HLYK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The HealthLynked Corp. (HLYK) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports, annual and quarterly reports, and insider-related documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information about HealthLynked’s healthcare technology business, governance, executive appointments, and strategic direction.
For HealthLynked, Form 8-K current reports are particularly important for tracking material events such as changes in leadership, board composition, or key corporate actions. For example, a recent 8-K describes the appointment of a Chief Operating Officer and the addition of new directors with backgrounds in insurance, employer benefits, and financial services, illustrating how the company is aligning governance and management with its focus on AI-enabled care coordination and payer partnerships.
Investors can also review 10-K annual reports and 10-Q quarterly reports (when filed) to understand HealthLynked’s business description, risk factors, segment information, and discussion of operations related to its patient network, telemedicine services, AI tools, research initiatives, and MedOfficeDirect e-commerce platform. These documents provide context on how the company positions its technology, intellectual property, and enterprise solutions in the healthcare market.
Stock Titan enhances this information with AI-powered summaries that help explain complex sections of lengthy filings, highlight key changes from prior periods, and surface notable disclosures without replacing the original documents. Users can also monitor Form 4 insider transaction filings and proxy materials when available, gaining visibility into equity awards, director compensation structures, and other governance topics. Together, these filings and AI insights support a clearer view of HLYK’s regulatory history and corporate evolution.
HealthLynked Corp. reported several leadership changes. The company appointed Duncan McGillivray as Chief Operating Officer effective December 8, 2025. He has more than 30 years of experience in healthcare, capital markets, and large-scale project finance, including work on a targeted
His initial base salary is
HealthLynked Corp. (HLYKD) reported lower sales and continued losses for the quarter ended September 30, 2025. Total revenue was $388,545 versus $590,124 a year earlier, as patient service, subscription, and product revenue all declined. For the first nine months of 2025, revenue was $1,755,113 compared with $2,389,434 in the prior-year period.
The company posted a quarterly net loss of $851,800 and a nine‑month net loss of $2,603,777, though both were smaller than the prior year. Operating expenses fell year over year, helped by the absence of a $716,000 impairment charge recorded in 2024 and lower practice and overhead costs.
HealthLynked’s balance sheet remains strained. As of September 30, 2025, cash was $10,911, total assets were $1,764,557, and shareholders’ deficit widened to $5,433,415. Current liabilities of $6,744,301 included significant related‑party convertible debt, third‑party notes, and lease obligations. Management disclosed a substantial doubt about the company’s ability to continue as a going concern through November 19, 2026 without additional capital.
During the period, HealthLynked executed a 1‑for‑100 reverse stock split, reducing outstanding common shares from 284,750,832 to 2,847,873, and later agreed to sell its BTG physical therapy practice assets for $125,000 in cash.
FAQ
What is the current stock price of Healthlynked (HLYK)?
What is the market cap of Healthlynked (HLYK)?
